U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Usher syndrome type 1D(USH1D)

MedGen UID:
322051
Concept ID:
C1832845
Disease or Syndrome
Synonyms: USH1D; USHER SYNDROME, TYPE ID
 
Genes (locations): CDH23 (10q22.1); PCDH15 (10q21.1)
 
Monarch Initiative: MONDO:0010984
OMIM®: 601067

Disease characteristics

Excerpted from the GeneReview: Usher Syndrome Type I
Usher syndrome type I (USH1) is characterized by congenital, bilateral, profound sensorineural hearing loss, vestibular areflexia, and adolescent-onset retinitis pigmentosa (RP). Unless fitted with a cochlear implant, individuals do not typically develop speech. RP, a progressive, bilateral, symmetric degeneration of rod and cone functions of the retina, develops in adolescence, resulting in progressively constricted visual fields and impaired visual acuity. [from GeneReviews]
Authors:
Robert K Koenekoop  |  Moises A Arriaga  |  Karmen M Trzupek, et. al.   view full author information

Additional descriptions

From OMIM
Usher syndrome type I is an autosomal recessive condition characterized by profound congenital hearing impairment with unintelligible speech, early retinitis pigmentosa (usually evident within the first decade), and constant vestibular dysfunction. Type I is distinguished from type II (276901) on the basis of severity of hearing loss and the extent of vestibular involvement. Type I patients are profoundly deaf, whereas type II patients are 'hard of hearing.' Vestibular function is defective in type I patients, whereas type II patients have normal vestibular function (Moller et al., 1989). Patients with type III (USH3; 276902) have progressive hearing loss. For a discussion of genetic heterogeneity of Usher syndrome type I, see 276900.  http://www.omim.org/entry/601067
From MedlinePlus Genetics
People with Usher syndrome type III experience hearing loss and vision loss beginning somewhat later in life. Unlike the other forms of Usher syndrome, type III is usually associated with normal hearing at birth. Hearing loss typically begins during late childhood or adolescence, after the development of speech, and becomes more severe over time. By middle age, most affected individuals have profound hearing loss. Vision loss caused by retinitis pigmentosa also develops in late childhood or adolescence. Some people with Usher syndrome type III develop vestibular abnormalities that cause problems with balance.

Usher syndrome type II is characterized by hearing loss from birth and progressive vision loss that begins in adolescence or adulthood. The hearing loss associated with this form of Usher syndrome ranges from mild to severe and mainly affects the ability to hear high-frequency sounds. For example, it is difficult for affected individuals to hear high, soft speech sounds, such as those of the letters d and t. The degree of hearing loss varies within and among families with this condition, and it may become more severe over time. Unlike the other forms of Usher syndrome, type II is not associated with vestibular abnormalities that cause difficulties with balance.

Most individuals with Usher syndrome type I are born with severe to profound hearing loss. Worsening vision loss caused by retinitis pigmentosa becomes apparent in childhood. This type of Usher syndrome also causes abnormalities of the vestibular system, which is the part of the inner ear that helps maintain the body's balance and orientation in space. As a result of the vestibular abnormalities, children with the condition have trouble with balance. They begin sitting independently and walking later than usual, and they may have difficulty riding a bicycle and playing certain sports.

Researchers have identified three major types of Usher syndrome, designated as types I, II, and III. These types are distinguished by the severity of hearing loss, the presence or absence of balance problems, and the age at which signs and symptoms appear. The types are further divided into subtypes based on their genetic cause.

Usher syndrome is a condition characterized by partial or total hearing loss and vision loss that worsens over time. The hearing loss is classified as sensorineural, which means that it is caused by abnormalities of the inner ear. The loss of vision is caused by an eye disease called retinitis pigmentosa (RP), which affects the layer of light-sensitive tissue at the back of the eye (the retina). Vision loss occurs as the light-sensing cells of the retina gradually break down. Loss of night vision begins first, followed by blind spots that develop in the side (peripheral) vision. Over time, these blind spots enlarge and merge to produce tunnel vision. In some cases, vision is further impaired by clouding of the lens of the eye (cataracts). However, many people with retinitis pigmentosa retain some central vision throughout their lives.  https://medlineplus.gov/genetics/condition/usher-syndrome

Clinical features

From HPO
Hearing impairment
MedGen UID:
235586
Concept ID:
C1384666
Disease or Syndrome
A decreased magnitude of the sensory perception of sound.
Abnormal vestibular function
MedGen UID:
334848
Concept ID:
C1843865
Finding
An abnormality of the functioning of the vestibular apparatus.
Rod-cone dystrophy
MedGen UID:
1632921
Concept ID:
C4551714
Disease or Syndrome
An inherited retinal disease subtype in which the rod photoreceptors appear to be more severely affected than the cone photoreceptors. Typical presentation is with nyctalopia (due to rod dysfunction) followed by loss of mid-peripheral field of vision, which gradually extends and leaves many patients with a small central island of vision due to the preservation of macular cones.

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  

Professional guidelines

PubMed

Malm E, Ponjavic V, Möller C, Kimberling WJ, Andréasson S
Ophthalmic Genet 2011 Jun;32(2):65-74. Epub 2010 Dec 21 doi: 10.3109/13816810.2010.536064. PMID: 21174530

Curated

Bolz HJ, Roux AF
Eur J Hum Genet 2011 Aug;19(8) Epub 2011 Mar 9 doi: 10.1038/ejhg.2011.15. PMID: 21697857Free PMC Article

Recent clinical studies

Etiology

Noonan KY, Russo J, Shen J, Rehm H, Halbach S, Hopp E, Noon S, Hoover J, Eskey C, Saunders JE
Otol Neurotol 2016 Dec;37(10):1583-1588. doi: 10.1097/MAO.0000000000001210. PMID: 27631835
von Brederlow B, Bolz H, Janecke A, La O Cabrera A, Rudolph G, Lorenz B, Schwinger E, Gal A
Hum Mutat 2002 Mar;19(3):268-73. doi: 10.1002/humu.10049. PMID: 11857743

Diagnosis

Menghini M, Cehajic-Kapetanovic J, Yusuf IH, MacLaren RE
Ophthalmic Genet 2019 Dec;40(6):545-548. Epub 2019 Nov 22 doi: 10.1080/13816810.2019.1692359. PMID: 31755791
Noonan KY, Russo J, Shen J, Rehm H, Halbach S, Hopp E, Noon S, Hoover J, Eskey C, Saunders JE
Otol Neurotol 2016 Dec;37(10):1583-1588. doi: 10.1097/MAO.0000000000001210. PMID: 27631835
Branson SV, McClintic JI, Stamper TH, Haldeman-Englert CR, John VJ
Ophthalmic Surg Lasers Imaging Retina 2016 Feb;47(2):183-6. doi: 10.3928/23258160-20160126-14. PMID: 26878454
Bork JM, Morell RJ, Khan S, Riazuddin S, Wilcox ER, Friedman TB, Griffith AJ
Adv Otorhinolaryngol 2002;61:145-52. doi: 10.1159/000066829. PMID: 12408077
Cremers FP
Curr Opin Neurol 1998 Feb;11(1):11-6. doi: 10.1097/00019052-199802000-00003. PMID: 9484611

Therapy

Maddalena A, Tornabene P, Tiberi P, Minopoli R, Manfredi A, Mutarelli M, Rossi S, Simonelli F, Naggert JK, Cacchiarelli D, Auricchio A
Mol Ther 2018 Feb 7;26(2):524-541. Epub 2017 Dec 5 doi: 10.1016/j.ymthe.2017.11.019. PMID: 29292161Free PMC Article

Prognosis

Menghini M, Cehajic-Kapetanovic J, Yusuf IH, MacLaren RE
Ophthalmic Genet 2019 Dec;40(6):545-548. Epub 2019 Nov 22 doi: 10.1080/13816810.2019.1692359. PMID: 31755791
Bolz H, von Brederlow B, Ramírez A, Bryda EC, Kutsche K, Nothwang HG, Seeliger M, del C-Salcedó Cabrera M, Vila MC, Molina OP, Gal A, Kubisch C
Nat Genet 2001 Jan;27(1):108-12. doi: 10.1038/83667. PMID: 11138009

Clinical prediction guides

Menghini M, Cehajic-Kapetanovic J, Yusuf IH, MacLaren RE
Ophthalmic Genet 2019 Dec;40(6):545-548. Epub 2019 Nov 22 doi: 10.1080/13816810.2019.1692359. PMID: 31755791
Maddalena A, Tornabene P, Tiberi P, Minopoli R, Manfredi A, Mutarelli M, Rossi S, Simonelli F, Naggert JK, Cacchiarelli D, Auricchio A
Mol Ther 2018 Feb 7;26(2):524-541. Epub 2017 Dec 5 doi: 10.1016/j.ymthe.2017.11.019. PMID: 29292161Free PMC Article
Oshima A, Jaijo T, Aller E, Millan JM, Carney C, Usami S, Moller C, Kimberling WJ
Hum Mutat 2008 Jun;29(6):E37-46. doi: 10.1002/humu.20761. PMID: 18429043Free PMC Article
von Brederlow B, Bolz H, Janecke A, La O Cabrera A, Rudolph G, Lorenz B, Schwinger E, Gal A
Hum Mutat 2002 Mar;19(3):268-73. doi: 10.1002/humu.10049. PMID: 11857743
Bolz H, von Brederlow B, Ramírez A, Bryda EC, Kutsche K, Nothwang HG, Seeliger M, del C-Salcedó Cabrera M, Vila MC, Molina OP, Gal A, Kubisch C
Nat Genet 2001 Jan;27(1):108-12. doi: 10.1038/83667. PMID: 11138009

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...